419 related articles for article (PubMed ID: 26636901)
1. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.
Tibbitts J; Canter D; Graff R; Smith A; Khawli LA
MAbs; 2016; 8(2):229-45. PubMed ID: 26636901
[TBL] [Abstract][Full Text] [Related]
2. ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.
Lee JW
Bioanalysis; 2013 Aug; 5(16):2003-14. PubMed ID: 23937135
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond.
Jiang R; Hooshfar S; Rebecca Eno M; Yun C; Sonego Zimmermann E; Shinkyo R
Curr Drug Metab; 2023; 24(7):536-552. PubMed ID: 37076460
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
Lin JH
Curr Drug Metab; 2009 Sep; 10(7):661-91. PubMed ID: 19702530
[TBL] [Abstract][Full Text] [Related]
6. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
Vugmeyster Y; Harrold J; Xu X
AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
[TBL] [Abstract][Full Text] [Related]
7. Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.
Kraynov E; Kamath AV; Walles M; Tarcsa E; Deslandes A; Iyer RA; Datta-Mannan A; Sriraman P; Bairlein M; Yang JJ; Barfield M; Xiao G; Escandon E; Wang W; Rock DA; Chemuturi NV; Moore DJ
Drug Metab Dispos; 2016 May; 44(5):617-23. PubMed ID: 26669328
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
9. Biologics: an update and challenge of their pharmacokinetics.
Shi S
Curr Drug Metab; 2014 Mar; 15(3):271-90. PubMed ID: 24745789
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
Glassman PM; Balthasar JP
Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Peptide-Fc fusion proteins.
Wu B; Sun YN
J Pharm Sci; 2014 Jan; 103(1):53-64. PubMed ID: 24285510
[TBL] [Abstract][Full Text] [Related]
12. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
13. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery.
Lucas AJ; Sproston JL; Barton P; Riley RJ
Expert Opin Drug Discov; 2019 Dec; 14(12):1313-1327. PubMed ID: 31538500
[No Abstract] [Full Text] [Related]
14. Universal Automated Immunoaffinity Purification-CE-MS Platform for Accelerating Next Generation Biologic Design.
Han M; Wang Y; Cook K; Bala N; Soto M; Rock DA; Pearson JT; Rock BM
Anal Chem; 2021 Apr; 93(13):5562-5569. PubMed ID: 33764735
[TBL] [Abstract][Full Text] [Related]
15. Insecticide ADME for support of early-phase discovery: combining classical and modern techniques.
David MD
Pest Manag Sci; 2017 Apr; 73(4):692-699. PubMed ID: 27346229
[TBL] [Abstract][Full Text] [Related]
16. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
Mou S; Huang Y; Rosenbaum AI
Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
[TBL] [Abstract][Full Text] [Related]
17. ADME of biologics-what have we learned from small molecules?
Prueksaritanont T; Tang C
AAPS J; 2012 Sep; 14(3):410-9. PubMed ID: 22484625
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities.
Rock BM; Foti RS
Drug Metab Dispos; 2019 Oct; 47(10):1097-1099. PubMed ID: 31399505
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.
Dostalek M; Prueksaritanont T; Kelley RF
MAbs; 2017 Jul; 9(5):756-766. PubMed ID: 28463063
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.
Cronin JM; Yu AM
Drug Metab Dispos; 2023 Jun; 51(6):685-699. PubMed ID: 36948592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
